var data={"title":"Bone disease in diabetes mellitus","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Bone disease in diabetes mellitus</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/contributors\" class=\"contributor contributor_credentials\">Lesley D Hordon, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/contributors\" class=\"contributor contributor_credentials\">David M Nathan, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/contributors\" class=\"contributor contributor_credentials\">Marc K Drezner, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/contributors\" class=\"contributor contributor_credentials\">Jean E Mulder, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Apr 03, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The association between diabetes mellitus and osteoporosis remains controversial [<a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/1\" class=\"abstract_t\">1</a>]. Although the metabolic abnormalities of diabetes potentially affect bone metabolism, structure, and mineral density, the extent of their contribution to the increase in fracture risk noted in individuals with type 1 and type 2 diabetes is still debated. In addition to changes in bone metabolism, there are several other factors that may be important:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The onset of diabetes in adolescence may result in a decreased peak bone mass.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The degree of bone loss differs between type 1 and type 2 diabetes. In some studies, type 2 diabetes has been associated with an increase in bone mineral density (BMD) [<a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/2\" class=\"abstract_t\">2</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Bone fragility, particularly in type 2 diabetes, may contribute to fracture risk independent of BMD, and BMD may not reflect fracture risk in some individuals.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Bone metabolism may be affected by the late complications of diabetes (eg, renal failure).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The risk of fracture may be increased by falling, secondary to visual impairment, cerebrovascular disease, or neuropathy.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Localized bone loss related to diabetic neuropathy may increase the risk of fracture at the foot and ankle.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Specific treatments may influence fracture rates.</p><p/><p>This topic will review the effects of type 1 and type 2 diabetes on bone (<a href=\"image.htm?imageKey=ENDO%2F51539\" class=\"graphic graphic_table graphicRef51539 \">table 1</a>). The musculoskeletal complications of diabetes are discussed separately. (See <a href=\"topic.htm?path=musculoskeletal-complications-in-diabetes-mellitus\" class=\"medical medical_review\">&quot;Musculoskeletal complications in diabetes mellitus&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">BONE METABOLISM IN DIABETES MELLITUS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Studies in bone histomorphometry in type 1 diabetes have generally [<a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/1\" class=\"abstract_t\">1</a>], but not always [<a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/3\" class=\"abstract_t\">3</a>], shown a low turnover of bone with reduction in bone formation and, to a lesser degree, bone resorption. In several studies, low bone turnover is manifested by reduced serum concentrations of markers of bone turnover [<a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/4\" class=\"abstract_t\">4</a>]. As an example, in a systematic review and meta-analysis of 66 studies evaluating bone metabolism in patients with diabetes, markers of both bone formation (osteocalcin) and resorption (C-telopeptide) were decreased in patients with type 1 and type 2 diabetes compared with controls [<a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/4\" class=\"abstract_t\">4</a>]. (See <a href=\"topic.htm?path=bone-physiology-and-biochemical-markers-of-bone-turnover\" class=\"medical medical_review\">&quot;Bone physiology and biochemical markers of bone turnover&quot;</a>.)</p><p>Similar changes have been noted in diabetic patients who progress to end-stage renal disease. Compared with normal subjects, patients with diabetes are more likely to have adynamic bone disease (including that associated with aluminum deposition) [<a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/5,6\" class=\"abstract_t\">5,6</a>], whereas hyperparathyroid bone disease is infrequent, occurring in less than 10 percent of cases [<a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/6-8\" class=\"abstract_t\">6-8</a>]. (See <a href=\"topic.htm?path=overview-of-chronic-kidney-disease-mineral-and-bone-disorder-ckd-mbd#H312947\" class=\"medical medical_review\">&quot;Overview of chronic kidney disease-mineral and bone disorder (CKD-MBD)&quot;, section on 'Abnormalities in bone turnover, mineralization, volume linear growth, or strength'</a>.)</p><p>The mechanism for the reduced bone turnover in diabetes is likely multifactorial. Studies in uremic rats suggest that lack of insulin may diminish bone turnover [<a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/9\" class=\"abstract_t\">9</a>]. However, insulin deficiency may also be important earlier since decreased bone formation can be demonstrated in type 1 diabetics before the onset of clinical renal disease [<a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/1,5,7\" class=\"abstract_t\">1,5,7</a>]. The anabolic effects of insulin may be mediated through the insulin-like growth factor-1 (IGF-1) pathway, and in type 1 diabetes, low levels of insulin and IGF-1 may impair osteoblast function [<a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/10\" class=\"abstract_t\">10</a>]. In contrast, obesity-induced insulin resistance in type 2 diabetes leads to increased levels of insulin and IGF-1, with a possible anabolic effect on bone (<a href=\"image.htm?imageKey=ENDO%2F51539\" class=\"graphic graphic_table graphicRef51539 \">table 1</a>).</p><p>The accumulation of advanced glycation end products (AGEs) in collagen as a result of hyperglycemia also may contribute to reduced bone formation. Low bone turnover, with a reduction in unmineralized bone matrix, and increased collagen glycosylation may contribute to increased fragility of diabetic bone [<a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/1,11,12\" class=\"abstract_t\">1,11,12</a>]. The increase in bone fragility may not be predicted by measurement of bone density [<a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/13\" class=\"abstract_t\">13</a>].</p><p>Another factor that can affect bone metabolism in diabetes is hypercalciuria [<a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/3,14\" class=\"abstract_t\">3,14</a>]. The mechanism by which this occurs is not clear, but it can be ameliorated with insulin [<a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/14\" class=\"abstract_t\">14</a>]. Both the loss of bone mineral and functional hypoparathyroidism may play a contributory role [<a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/3,15\" class=\"abstract_t\">3,15</a>].</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">BONE DENSITY</span></p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Type 1 diabetes</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Children and adolescents with type 1 diabetes have reduced bone mineral density (BMD) at the forearm and lumbar spine [<a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/16-18\" class=\"abstract_t\">16-18</a>], which appears constant with time [<a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/16\" class=\"abstract_t\">16</a>]. Variable findings have been reported ranging from reductions in trabecular but not cortical BMD [<a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/19\" class=\"abstract_t\">19</a>] to no deficit reported when BMD is corrected for weight [<a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/20\" class=\"abstract_t\">20</a>]. It is hypothesized that any defect in BMD is due to a failure to acquire endosteal bone during growth (<a href=\"image.htm?imageKey=ENDO%2F51539\" class=\"graphic graphic_table graphicRef51539 \">table 1</a>).</p><p>In adults with type 1 diabetes, lumbar BMD is usually normal [<a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/21-23\" class=\"abstract_t\">21-23</a>], while femoral BMD is reduced [<a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/2,21-24\" class=\"abstract_t\">2,21-24</a>]. In most studies, there was no relationship between BMD and the duration of diabetes or glycemic control [<a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/16,17,20-22,25\" class=\"abstract_t\">16,17,20-22,25</a>]. However, these findings have not been uniformly found [<a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/19,24-26\" class=\"abstract_t\">19,24-26</a>]. One study of premenopausal women, for example, found increased lumbar BMD and normal femoral BMD [<a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/25\" class=\"abstract_t\">25</a>]. In another study, lumbar BMD was low; the study included a high proportion of patients with retinopathy and neuropathy, suggesting that microvascular disease can influence BMD [<a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/24\" class=\"abstract_t\">24</a>]. A link between neuropathy and low femoral neck BMD has also been reported [<a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/22\" class=\"abstract_t\">22</a>].</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Type 2 diabetes</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The majority of studies in type 2 diabetes have found that BMD is normal or increased at the lumbar spine [<a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/27-30\" class=\"abstract_t\">27-30</a>], femoral neck [<a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/2,27,29-31\" class=\"abstract_t\">2,27,29-31</a>], and mid and distal radius [<a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/29\" class=\"abstract_t\">29</a>]. These findings applied to both women and men [<a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/27-30\" class=\"abstract_t\">27-30</a>]. As expected, BMD correlated with body mass index (BMI) [<a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/28\" class=\"abstract_t\">28</a>]. However, in those studies that corrected for BMI, increased BMD was independent of obesity [<a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/27,29,30\" class=\"abstract_t\">27,29,30</a>].</p><p>A study of older, well-functioning patients with type 2 diabetes showed higher hip, total body, and volumetric spine BMD in black and white men and women compared with their appropriate controls, although a lower spine bone volume was found in diabetes subjects, which may possibly decrease bone strength [<a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/32\" class=\"abstract_t\">32</a>].</p><p>A longitudinal, 12-year study of 109 patients with both type 1 and type 2 diabetes reported two major findings [<a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/11\" class=\"abstract_t\">11</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Radial BMD was lower than in normal subjects in both groups at baseline</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The rate of decline in radial BMD over time was similar to that in normal subjects in type 1 diabetes and less than that in normal subjects in type 2 diabetes, such that the original deficit was reversed</p><p/><p>The authors proposed that impaired osteoblast recruitment or function was responsible for the original reduction in BMD and that low bone turnover diminished age-related bone loss in older patients with type 2 diabetes. One limitation of these findings is that BMD could only be measured in survivors, which comprised just over one-half of the original study population.</p><p>Research using high-resolution peripheral quantitative computed tomography (HR-pQCT) has suggested that a deficit in cortical bone, resulting in increased cortical porosity, may contribute to fracture risk in type 2 diabetes, explaining in part the reduction in bone strength, which is not detected by dual-energy x-ray absorptiometry (DXA) [<a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/33\" class=\"abstract_t\">33</a>]. Another study using HR-pQCT compared patients with type 2 diabetes (with and without microvascular complications) with controls and found that only the group with microvascular complications had cortical bone deficits [<a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/34\" class=\"abstract_t\">34</a>].</p><p>One group of individuals with type 2 diabetes who appear to be at risk for an increased rate of bone loss is women treated with thiazolidinediones. Additional studies are warranted to further explore this area. (See <a href=\"topic.htm?path=thiazolidinediones-in-the-treatment-of-diabetes-mellitus#H18\" class=\"medical medical_review\">&quot;Thiazolidinediones in the treatment of diabetes mellitus&quot;, section on 'Safety'</a>.)</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h1\">FRACTURE</span></p><p class=\"headingAnchor\" id=\"H1901780573\"><span class=\"h2\">Increased risk</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although some studies have not found a relationship [<a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/30,35,36\" class=\"abstract_t\">30,35,36</a>], the majority have demonstrated an increased risk of fracture in patients with diabetes [<a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/37-53\" class=\"abstract_t\">37-53</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In the Women's Health Initiative (WHI) Observational Study, a prospective cohort study of 93,676 postmenopausal women, women with type 2 diabetes (n = 5285) had an increased risk of fracture after seven years of follow-up compared with women without diabetes (adjusted relative risk [RR] 1.20, 95% CI 1.11-1.30) [<a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/47\" class=\"abstract_t\">47</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A systematic review and a meta-analysis of diabetes and fracture showed similar increases in risk of hip fracture in patients with either type 1 diabetes (RRs 6.3 and 6.9, respectively) or type 2 diabetes (RRs 1.7 and 1.4, respectively) [<a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/46,54\" class=\"abstract_t\">46,54</a>]. Results from the meta-analysis also showed that bone mineral density (BMD) was increased at the spine and hip in type 2 diabetics but decreased at both sites in type 1 diabetics [<a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/46\" class=\"abstract_t\">46</a>]. Fracture risk was higher and BMD lower in those with diabetic complications.</p><p/><p>In population-based studies, an association between risk of fractures (proximal humerus, vertebral, and hip) and longer diabetes duration, diabetic retinopathy, advanced cortical cataract, neuropathy, and insulin treatment has been described [<a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/44,50\" class=\"abstract_t\">44,50</a>]. In one study, the association between retinopathy and fracture risk remained significant after adjusting for visual acuity, suggesting that retinopathy may be acting as a proxy for severe diabetic microvascular disease [<a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/44\" class=\"abstract_t\">44</a>]. An increased risk of falling in older diabetic women also has been reported [<a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/55\" class=\"abstract_t\">55</a>].</p><p>In a retrospective study, an increased incidence of foot fractures, predominantly metatarsal, has also been described in diabetic athletes [<a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/41\" class=\"abstract_t\">41</a>]. Fractures were more common in men and were associated with a long duration of disease. In addition, diabetic neuropathy has been associated with osteopenia in both hands and feet, metatarsal fractures, and a subsequent risk of osteopathy [<a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/40\" class=\"abstract_t\">40</a>].</p><p>The possibility that fracture risk is associated with disease duration and presence of long-term complications was also illustrated by a retrospective, population-based cohort study of 82,000 adults with diabetes and over 236,000 matched nondiabetic controls [<a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/56\" class=\"abstract_t\">56</a>]. The risk of osteoporotic fractures (RR 1.15, 95% CI 1.09-1.22) and hip fractures (RR 1.40, 95% CI 1.28-1.53) was increased in adults with long-term diabetes, whereas fracture risk was decreased in newly diagnosed diabetes (RRs 0.91, 95% CI 0.86-0.95 and 0.83, 95% CI 0.75-0.92 for osteoporotic and hip fractures, respectively). Poor glycemic control has been linked to an increase in fracture risk in patients &ge;65 years with type 2 diabetes [<a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/57\" class=\"abstract_t\">57</a>].</p><p>Fracture risk may also be related to therapy. A Diabetes Outcome Progression Trial (ADOPT) reported a higher rate of fractures in newly diagnosed women with diabetes randomly assigned to receive four years of <a href=\"topic.htm?path=rosiglitazone-drug-information\" class=\"drug drug_general\">rosiglitazone</a>, as opposed to <a href=\"topic.htm?path=metformin-drug-information\" class=\"drug drug_general\">metformin</a> or <a href=\"topic.htm?path=glyburide-glibenclamide-drug-information\" class=\"drug drug_general\">glyburide</a>. (See <a href=\"topic.htm?path=initial-management-of-blood-glucose-in-adults-with-type-2-diabetes-mellitus\" class=\"medical medical_review\">&quot;Initial management of blood glucose in adults with type 2 diabetes mellitus&quot;</a> and <a href=\"topic.htm?path=thiazolidinediones-in-the-treatment-of-diabetes-mellitus#H18\" class=\"medical medical_review\">&quot;Thiazolidinediones in the treatment of diabetes mellitus&quot;, section on 'Safety'</a>.)</p><p>Taken together, the above data suggest that BMD is lower in patients with type 1 diabetes and normal or increased in patients with type 2 diabetes. However, fracture risk appears increased in both groups, possibly related to factors in addition to BMD, such as duration of diabetes, diabetic complications, bone quality, treatment, and risk of falling (<a href=\"image.htm?imageKey=ENDO%2F51539\" class=\"graphic graphic_table graphicRef51539 \">table 1</a>).</p><p class=\"headingAnchor\" id=\"H176095728\"><span class=\"h2\">Clinical evaluation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The evaluation of fracture risk in patients with diabetes mellitus is the same as in patients without diabetes and includes assessment of BMD and clinical risk factors. A fracture risk assessment tool, such as <a href=\"https://www.shef.ac.uk/FRAX/&amp;token=FWNID0ZRoEvvwjKjY4KwHW1btRHFjfC6xC2eF35OuVRpFQ19sAxtt5sC4Hyf03iW&amp;TOPIC_ID=2051\" target=\"_blank\" class=\"external\">FRAX</a>, can be used to express the probability of fracture over a specified period of time. However, for a given BMD T-score or FRAX score, the risk of fracture may be higher in older adults with diabetes compared with those without diabetes [<a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/58,59\" class=\"abstract_t\">58,59</a>]. At present, the FRAX algorithm does not include diabetes as a risk factor. More research is required in collecting new population cohorts worldwide before this risk factor can be included. It has, however, been suggested that if a diabetic patient is just below the FRAX-based intervention threshold, the clinician may take into account the effect of diabetes on fracture risk and recommend treatment [<a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/60\" class=\"abstract_t\">60</a>]. Fracture risk assessment, including a description of FRAX and the clinical applications of fracture risk assessment, is reviewed in detail elsewhere. (See <a href=\"topic.htm?path=osteoporotic-fracture-risk-assessment#H2\" class=\"medical medical_review\">&quot;Osteoporotic fracture risk assessment&quot;, section on 'Assessment of fracture risk'</a>.)</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Fracture healing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Prolonged fracture healing has been described in both type 1 and type 2 diabetes [<a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/61,62\" class=\"abstract_t\">61,62</a>]. This occurred in patients with displaced fractures and those treated by open reduction, while healing time was normal in patients with nondisplaced fractures. Reduced bone turnover, as mentioned above, may account for the delay in healing [<a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/62\" class=\"abstract_t\">62</a>].</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h1\">PREVENTION AND TREATMENT OF OSTEOPOROSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>At present, there are few studies specifically addressing the prevention and treatment of osteoporosis in individuals with diabetes. As examples:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a subgroup analysis of a larger study, the Fracture Intervention Trial, three years of <a href=\"topic.htm?path=alendronate-drug-information\" class=\"drug drug_general\">alendronate</a> therapy resulted in similar improvements in bone density in postmenopausal women with (n = 297) or without diabetes (n = 6161) [<a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/63\" class=\"abstract_t\">63</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a post hoc analysis of <a href=\"topic.htm?path=risedronate-drug-information\" class=\"drug drug_general\">risedronate</a> trials in Japan, risedronate was safe and effective in suppressing bone turnover and increasing bone mineral density (BMD) in osteoporosis patients with coexistent diabetes (n = 53) compared with nondiabetics (n = 832) [<a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/64\" class=\"abstract_t\">64</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a large Danish cohort study, there was no difference in the effects of bisphosphonate treatment or <a href=\"topic.htm?path=raloxifene-drug-information\" class=\"drug drug_general\">raloxifene</a> treatment in fracture reduction between women and men with type 1 and type 2 diabetes and women and men without diabetes receiving these treatments [<a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/65\" class=\"abstract_t\">65</a>]. There were insufficient people receiving strontium in the cohort to allow analysis.</p><p/><p>Serious adverse events from bisphosphonate treatment do not seem to be increased in patients with diabetes [<a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/63-65\" class=\"abstract_t\">63-65</a>]. (See <a href=\"topic.htm?path=risks-of-bisphosphonate-therapy-in-patients-with-osteoporosis\" class=\"medical medical_review\">&quot;Risks of bisphosphonate therapy in patients with osteoporosis&quot;</a>.)</p><p>The general recommendations regarding healthy lifestyle, exercise, and calcium and vitamin D supplementation are applicable to postmenopausal women and men with diabetes [<a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/66,67\" class=\"abstract_t\">66,67</a>]. In the absence of studies specifically targeting osteoporosis in individuals with diabetes, treatment recommendations should follow other guidelines, such as those for postmenopausal women and men. (See <a href=\"topic.htm?path=overview-of-the-management-of-osteoporosis-in-postmenopausal-women\" class=\"medical medical_review\">&quot;Overview of the management of osteoporosis in postmenopausal women&quot;</a> and <a href=\"topic.htm?path=treatment-of-osteoporosis-in-men\" class=\"medical medical_review\">&quot;Treatment of osteoporosis in men&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h1\">DIFFUSE IDIOPATHIC SKELETAL HYPEROSTOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Diffuse idiopathic skeletal hyperostosis (DISH) is a common degenerative enthesopathy affecting both the axial and appendicular skeleton that may occur with increased frequency in diabetics. The etiology of DISH is not known. Its possible relationship with diabetes and obesity and its occurrence in patients with acromegaly have led to the evaluation of the pathogenetic role of insulin, insulin-like growth factor (IGF), and growth hormone. (See <a href=\"topic.htm?path=diffuse-idiopathic-skeletal-hyperostosis-dish\" class=\"medical medical_review\">&quot;Diffuse idiopathic skeletal hyperostosis (DISH)&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with diabetes typically have low bone turnover with reduction in bone formation and, to a lesser degree, bone resorption. The mechanism for the reduced bone turnover is likely multifactorial. In type 1 diabetes, low levels of insulin and insulin-like growth factor-1 (IGF-1) may impair osteoblast function. In both type 1 and type 2 diabetes, the accumulation of advanced glycation end products (AGEs) in collagen as a result of hyperglycemia also may contribute to reduced bone formation (<a href=\"image.htm?imageKey=ENDO%2F51539\" class=\"graphic graphic_table graphicRef51539 \">table 1</a>). (See <a href=\"#H2\" class=\"local\">'Bone metabolism in diabetes mellitus'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Bone mineral density (BMD), as measured by dual-energy x-ray absorptiometry (DXA), is lower in patients with type 1 diabetes and normal or increased in patients with type 2 diabetes, although cortical porosity may be increased. (See <a href=\"#H3\" class=\"local\">'Bone density'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Fracture risk is increased in both groups, possibly related to factors in addition to BMD, such as duration of diabetes, glycemic control, diabetic complications, bone quality, treatment, and risk of falling (<a href=\"image.htm?imageKey=ENDO%2F51539\" class=\"graphic graphic_table graphicRef51539 \">table 1</a>). (See <a href=\"#H6\" class=\"local\">'Fracture'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In the absence of studies specifically targeting osteoporosis in individuals with diabetes, treatment recommendations should follow other guidelines, such as those for postmenopausal women and men. (See <a href=\"topic.htm?path=overview-of-the-management-of-osteoporosis-in-postmenopausal-women\" class=\"medical medical_review\">&quot;Overview of the management of osteoporosis in postmenopausal women&quot;</a> and <a href=\"topic.htm?path=treatment-of-osteoporosis-in-men\" class=\"medical medical_review\">&quot;Treatment of osteoporosis in men&quot;</a>.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/1\" class=\"nounderline abstract_t\">Bouillon R. Diabetic bone disease. Calcif Tissue Int 1991; 49:155.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/2\" class=\"nounderline abstract_t\">Tuominen JT, Impivaara O, Puukka P, R&ouml;nnemaa T. Bone mineral density in patients with type 1 and type 2 diabetes. Diabetes Care 1999; 22:1196.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/3\" class=\"nounderline abstract_t\">McNair P. Bone mineral metabolism in human type 1 (insulin dependent) diabetes mellitus. Dan Med Bull 1988; 35:109.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/4\" class=\"nounderline abstract_t\">Hygum K, Starup-Linde J, Harsl&oslash;f T, et al. MECHANISMS IN ENDOCRINOLOGY: Diabetes mellitus, a state of low bone turnover - a systematic review and meta-analysis. Eur J Endocrinol 2017; 176:R137.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/5\" class=\"nounderline abstract_t\">Andress DL, Kopp JB, Maloney NA, et al. Early deposition of aluminum in bone in diabetic patients on hemodialysis. N Engl J Med 1987; 316:292.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/6\" class=\"nounderline abstract_t\">Pei Y, Hercz G, Greenwood C, et al. Renal osteodystrophy in diabetic patients. Kidney Int 1993; 44:159.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/7\" class=\"nounderline abstract_t\">Vincenti F, Arnaud SB, Recker R, et al. Parathyroid and bone response of the diabetic patient to uremia. Kidney Int 1984; 25:677.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/8\" class=\"nounderline abstract_t\">Vincenti F, Hattner R, Amend WJ Jr, et al. Decreased secondary hyperparathyroidism in diabetic patients receiving hemodialysis. JAMA 1981; 245:930.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/9\" class=\"nounderline abstract_t\">Jara A, Bover J, Felsenfeld AJ. Development of secondary hyperparathyroidism and bone disease in diabetic rats with renal failure. Kidney Int 1995; 47:1746.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/10\" class=\"nounderline abstract_t\">Epstein S, Leroith D. Diabetes and fragility fractures - a burgeoning epidemic? Bone 2008; 43:3.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/11\" class=\"nounderline abstract_t\">Krakauer JC, McKenna MJ, Buderer NF, et al. Bone loss and bone turnover in diabetes. Diabetes 1995; 44:775.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/12\" class=\"nounderline abstract_t\">Farlay D, Armas LA, Gineyts E, et al. Nonenzymatic Glycation and Degree of Mineralization Are Higher in Bone From Fractured Patients With Type 1 Diabetes Mellitus. J Bone Miner Res 2016; 31:190.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/13\" class=\"nounderline abstract_t\">Verhaeghe J, Suiker AM, Einhorn TA, et al. Brittle bones in spontaneously diabetic female rats cannot be predicted by bone mineral measurements: studies in diabetic and ovariectomized rats. J Bone Miner Res 1994; 9:1657.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/14\" class=\"nounderline abstract_t\">Raskin P, Stevenson MR, Barilla DE, Pak CY. The hypercalciuria of diabetes mellitus: its amelioration with insulin. Clin Endocrinol (Oxf) 1978; 9:329.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/15\" class=\"nounderline abstract_t\">Thalassinos NC, Hadjiyanni P, Tzanela M, et al. Calcium metabolism in diabetes mellitus: effect of improved blood glucose control. Diabet Med 1993; 10:341.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/16\" class=\"nounderline abstract_t\">Hui SL, Epstein S, Johnston CC Jr. A prospective study of bone mass in patients with type I diabetes. J Clin Endocrinol Metab 1985; 60:74.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/17\" class=\"nounderline abstract_t\">Weber G, Beccaria L, de'Angelis M, et al. Bone mass in young patients with type I diabetes. Bone Miner 1990; 8:23.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/18\" class=\"nounderline abstract_t\">Parthasarathy LS, Khadilkar VV, Chiplonkar SA, et al. Bone status of Indian children and adolescents with type 1 diabetes mellitus. Bone 2016; 82:16.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/19\" class=\"nounderline abstract_t\">Lettgen B, Hauffa B, M&ouml;hlmann C, et al. Bone mineral density in children and adolescents with juvenile diabetes: selective measurement of bone mineral density of trabecular and cortical bone using peripheral quantitative computed tomography. Horm Res 1995; 43:173.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/20\" class=\"nounderline abstract_t\">Ponder SW, McCormick DP, Fawcett HD, et al. Bone mineral density of the lumbar vertebrae in children and adolescents with insulin-dependent diabetes mellitus. J Pediatr 1992; 120:541.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/21\" class=\"nounderline abstract_t\">Compston JE, Smith EM, Matthews C, Schofield P. Whole body composition and regional bone mass in women with insulin-dependent diabetes mellitus. Clin Endocrinol (Oxf) 1994; 41:289.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/22\" class=\"nounderline abstract_t\">Forst T, Pf&uuml;tzner A, Kann P, et al. Peripheral osteopenia in adult patients with insulin-dependent diabetes mellitus. Diabet Med 1995; 12:874.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/23\" class=\"nounderline abstract_t\">Mastrandrea LD, Wactawski-Wende J, Donahue RP, et al. Young women with type 1 diabetes have lower bone mineral density that persists over time. Diabetes Care 2008; 31:1729.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/24\" class=\"nounderline abstract_t\">Kayath MJ, Dib SA, Vieira JG. Prevalence and magnitude of osteopenia associated with insulin-dependent diabetes mellitus. J Diabetes Complications 1994; 8:97.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/25\" class=\"nounderline abstract_t\">Gallacher SJ, Fenner JA, Fisher BM, et al. An evaluation of bone density and turnover in premenopausal women with type 1 diabetes mellitus. Diabet Med 1993; 10:129.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/26\" class=\"nounderline abstract_t\">Olmos JM, P&eacute;rez-Castrill&oacute;n JL, Garc&iacute;a MT, et al. Bone densitometry and biochemical bone remodeling markers in type 1 diabetes mellitus. Bone Miner 1994; 26:1.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/27\" class=\"nounderline abstract_t\">Rishaug U, Birkeland KI, Falch JA, Vaaler S. Bone mass in non-insulin-dependent diabetes mellitus. Scand J Clin Lab Invest 1995; 55:257.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/28\" class=\"nounderline abstract_t\">Wakasugi M, Wakao R, Tawata M, et al. Bone mineral density measured by dual energy x-ray absorptiometry in patients with non-insulin-dependent diabetes mellitus. Bone 1993; 14:29.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/29\" class=\"nounderline abstract_t\">Barrett-Connor E, Holbrook TL. Sex differences in osteoporosis in older adults with non-insulin-dependent diabetes mellitus. JAMA 1992; 268:3333.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/30\" class=\"nounderline abstract_t\">van Daele PL, Stolk RP, Burger H, et al. Bone density in non-insulin-dependent diabetes mellitus. The Rotterdam Study. Ann Intern Med 1995; 122:409.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/31\" class=\"nounderline abstract_t\">Melton LJ 3rd, Riggs BL, Leibson CL, et al. A bone structural basis for fracture risk in diabetes. J Clin Endocrinol Metab 2008; 93:4804.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/32\" class=\"nounderline abstract_t\">Strotmeyer ES, Cauley JA, Schwartz AV, et al. Diabetes is associated independently of body composition with BMD and bone volume in older white and black men and women: The Health, Aging, and Body Composition Study. J Bone Miner Res 2004; 19:1084.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/33\" class=\"nounderline abstract_t\">Burghardt AJ, Issever AS, Schwartz AV, et al. High-resolution peripheral quantitative computed tomographic imaging of cortical and trabecular bone microarchitecture in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2010; 95:5045.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/34\" class=\"nounderline abstract_t\">Shanbhogue VV, Hansen S, Frost M, et al. Compromised cortical bone compartment in type 2 diabetes mellitus patients with microvascular disease. Eur J Endocrinol 2016; 174:115.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/35\" class=\"nounderline abstract_t\">Heath H 3rd, Melton LJ 3rd, Chu CP. Diabetes mellitus and risk of skeletal fracture. N Engl J Med 1980; 303:567.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/36\" class=\"nounderline abstract_t\">Dobnig H, Piswanger-S&ouml;lkner JC, Roth M, et al. Type 2 diabetes mellitus in nursing home patients: effects on bone turnover, bone mass, and fracture risk. J Clin Endocrinol Metab 2006; 91:3355.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/37\" class=\"nounderline abstract_t\">Paganini-Hill A, Ross RK, Gerkins VR, et al. Menopausal estrogen therapy and hip fractures. Ann Intern Med 1981; 95:28.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/38\" class=\"nounderline abstract_t\">Meyer HE, Tverdal A, Falch JA. Risk factors for hip fracture in middle-aged Norwegian women and men. Am J Epidemiol 1993; 137:1203.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/39\" class=\"nounderline abstract_t\">Kelsey JL, Browner WS, Seeley DG, et al. Risk factors for fractures of the distal forearm and proximal humerus. The Study of Osteoporotic Fractures Research Group. Am J Epidemiol 1992; 135:477.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/40\" class=\"nounderline abstract_t\">Cundy TF, Edmonds ME, Watkins PJ. Osteopenia and metatarsal fractures in diabetic neuropathy. Diabet Med 1985; 2:461.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/41\" class=\"nounderline abstract_t\">Wolf SK. Diabetes mellitus and predisposition to athletic pedal fracture. J Foot Ankle Surg 1998; 37:16.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/42\" class=\"nounderline abstract_t\">Schwartz AV, Sellmeyer DE, Ensrud KE, et al. Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab 2001; 86:32.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/43\" class=\"nounderline abstract_t\">Nicodemus KK, Folsom AR, Iowa Women's Health Study. Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care 2001; 24:1192.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/44\" class=\"nounderline abstract_t\">Ivers RQ, Cumming RG, Mitchell P, et al. Diabetes and risk of fracture: The Blue Mountains Eye Study. Diabetes Care 2001; 24:1198.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/45\" class=\"nounderline abstract_t\">Vestergaard P, Rejnmark L, Mosekilde L. Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia 2005; 48:1292.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/46\" class=\"nounderline abstract_t\">Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes--a meta-analysis. Osteoporos Int 2007; 18:427.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/47\" class=\"nounderline abstract_t\">Bonds DE, Larson JC, Schwartz AV, et al. Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study. J Clin Endocrinol Metab 2006; 91:3404.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/48\" class=\"nounderline abstract_t\">Strotmeyer ES, Cauley JA, Schwartz AV, et al. Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the health, aging, and body composition study. Arch Intern Med 2005; 165:1612.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/49\" class=\"nounderline abstract_t\">Lipscombe LL, Jamal SA, Booth GL, Hawker GA. The risk of hip fractures in older individuals with diabetes: a population-based study. Diabetes Care 2007; 30:835.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/50\" class=\"nounderline abstract_t\">Melton LJ 3rd, Leibson CL, Achenbach SJ, et al. Fracture risk in type 2 diabetes: update of a population-based study. J Bone Miner Res 2008; 23:1334.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/51\" class=\"nounderline abstract_t\">Yamamoto M, Yamaguchi T, Yamauchi M, et al. Diabetic patients have an increased risk of vertebral fractures independent of BMD or diabetic complications. J Bone Miner Res 2009; 24:702.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/52\" class=\"nounderline abstract_t\">Vestergaard P, Rejnmark L, Mosekilde L. Diabetes and its complications and their relationship with risk of fractures in type 1 and 2 diabetes. Calcif Tissue Int 2009; 84:45.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/53\" class=\"nounderline abstract_t\">Napoli N, Strotmeyer ES, Ensrud KE, et al. Fracture risk in diabetic elderly men: the MrOS study. Diabetologia 2014; 57:2057.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/54\" class=\"nounderline abstract_t\">Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 2007; 166:495.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/55\" class=\"nounderline abstract_t\">Schwartz AV, Hillier TA, Sellmeyer DE, et al. Older women with diabetes have a higher risk of falls: a prospective study. Diabetes Care 2002; 25:1749.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/56\" class=\"nounderline abstract_t\">Leslie WD, Lix LM, Prior HJ, et al. Biphasic fracture risk in diabetes: a population-based study. Bone 2007; 40:1595.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/57\" class=\"nounderline abstract_t\">Li CI, Liu CS, Lin WY, et al. Glycated Hemoglobin Level and Risk of Hip Fracture in Older People with Type 2 Diabetes: A Competing Risk Analysis of Taiwan Diabetes Cohort Study. J Bone Miner Res 2015; 30:1338.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/58\" class=\"nounderline abstract_t\">Schwartz AV, Vittinghoff E, Bauer DC, et al. Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA 2011; 305:2184.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/59\" class=\"nounderline abstract_t\">Giangregorio LM, Leslie WD, Lix LM, et al. FRAX underestimates fracture risk in patients with diabetes. J Bone Miner Res 2012; 27:301.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/60\" class=\"nounderline abstract_t\">Leslie WD, Rubin MR, Schwartz AV, Kanis JA. Type 2 diabetes and bone. J Bone Miner Res 2012; 27:2231.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/61\" class=\"nounderline abstract_t\">Cozen L. Does diabetes delay fracture healing? Clin Orthop Relat Res 1972; 82:134.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/62\" class=\"nounderline abstract_t\">Loder RT. The influence of diabetes mellitus on the healing of closed fractures. Clin Orthop Relat Res 1988; :210.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/63\" class=\"nounderline abstract_t\">Keegan TH, Schwartz AV, Bauer DC, et al. Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women: the fracture intervention trial. Diabetes Care 2004; 27:1547.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/64\" class=\"nounderline abstract_t\">Inoue D, Muraoka R, Okazaki R, et al. Efficacy and Safety of Risedronate in Osteoporosis Subjects with Comorbid Diabetes, Hypertension, and/or Dyslipidemia: A Post Hoc Analysis of Phase III Trials Conducted in Japan. Calcif Tissue Int 2016; 98:114.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/65\" class=\"nounderline abstract_t\">Vestergaard P, Rejnmark L, Mosekilde L. Are antiresorptive drugs effective against fractures in patients with diabetes? Calcif Tissue Int 2011; 88:209.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/66\" class=\"nounderline abstract_t\">Lunt H. Women and diabetes. Diabet Med 1996; 13:1009.</a></li><li><a href=\"https://www.uptodate.com/contents/bone-disease-in-diabetes-mellitus/abstract/67\" class=\"nounderline abstract_t\">R&auml;kel A, Sheehy O, Rahme E, LeLorier J. Osteoporosis among patients with type 1 and type 2 diabetes. Diabetes Metab 2008; 34:193.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 2051 Version 11.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H10\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">BONE METABOLISM IN DIABETES MELLITUS</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">BONE DENSITY</a><ul><li><a href=\"#H4\" id=\"outline-link-H4\">Type 1 diabetes</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">Type 2 diabetes</a></li></ul></li><li><a href=\"#H6\" id=\"outline-link-H6\">FRACTURE</a><ul><li><a href=\"#H1901780573\" id=\"outline-link-H1901780573\">Increased risk</a></li><li><a href=\"#H176095728\" id=\"outline-link-H176095728\">Clinical evaluation</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">Fracture healing</a></li></ul></li><li><a href=\"#H8\" id=\"outline-link-H8\">PREVENTION AND TREATMENT OF OSTEOPOROSIS</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">DIFFUSE IDIOPATHIC SKELETAL HYPEROSTOSIS</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ENDO/2051|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ENDO/51539\" class=\"graphic graphic_table\">- Effects diabetes bone</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=bone-physiology-and-biochemical-markers-of-bone-turnover\" class=\"medical medical_review\">Bone physiology and biochemical markers of bone turnover</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diffuse-idiopathic-skeletal-hyperostosis-dish\" class=\"medical medical_review\">Diffuse idiopathic skeletal hyperostosis (DISH)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=initial-management-of-blood-glucose-in-adults-with-type-2-diabetes-mellitus\" class=\"medical medical_review\">Initial management of blood glucose in adults with type 2 diabetes mellitus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=musculoskeletal-complications-in-diabetes-mellitus\" class=\"medical medical_review\">Musculoskeletal complications in diabetes mellitus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=osteoporotic-fracture-risk-assessment\" class=\"medical medical_review\">Osteoporotic fracture risk assessment</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-chronic-kidney-disease-mineral-and-bone-disorder-ckd-mbd\" class=\"medical medical_review\">Overview of chronic kidney disease-mineral and bone disorder (CKD-MBD)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-the-management-of-osteoporosis-in-postmenopausal-women\" class=\"medical medical_review\">Overview of the management of osteoporosis in postmenopausal women</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=risks-of-bisphosphonate-therapy-in-patients-with-osteoporosis\" class=\"medical medical_review\">Risks of bisphosphonate therapy in patients with osteoporosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=thiazolidinediones-in-the-treatment-of-diabetes-mellitus\" class=\"medical medical_review\">Thiazolidinediones in the treatment of diabetes mellitus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-osteoporosis-in-men\" class=\"medical medical_review\">Treatment of osteoporosis in men</a></li></ul></div></div>","javascript":null}